ADMA Insider Filing: CFO Retains 239,419 Shares After RSU Tax Sale
Rhea-AI Filing Summary
ADMA Biologics (ADMA) Form 4 filing: CFO & Treasurer Brad L. Tade reported an automatic disposition of 7,123 common shares on 07/24/2025 using transaction code “F”, which indicates shares were withheld by the issuer solely to satisfy payroll-tax obligations triggered by restricted-stock-unit (RSU) vesting. The shares were valued at $17.31, an implied $123 k transaction value.
Following the tax withholding, Tade directly owns 239,419 shares. This total includes about 204,027 unvested RSUs granted in 2023-2025 that vest quarterly over four-year periods, plus 35,392 previously acquired shares. No derivative securities were bought or sold, and no open-market activity occurred.
The filing is routine, involves no cash proceeds to the insider, does not alter the company’s share count, and has limited market impact.
Positive
- CFO maintains a significant 239,419-share stake, preserving alignment with shareholder interests.
- Over 200,000 RSUs remain unvested, creating a long-term retention incentive tied to ADMA’s share performance.
Negative
- 7,123 shares were disposed (withheld for taxes), a minor reduction in insider exposure.
Insights
TL;DR: Routine tax-withholding sale; insider still heavily aligned with 239k shares—neutral market impact.
The F-code transaction shows mandatory share withholding rather than discretionary selling, removing any immediate bearish signal. With ~239k shares/RSUs remaining, the CFO retains substantial exposure to ADMA’s equity performance, which investors often view positively for alignment. Because the sale neither raises cash for the insider nor changes total shares outstanding, liquidity and valuation effects are negligible. I classify the filing as informational, not price-moving.
TL;DR: Standard Section 16 compliance; no governance red flags detected.
The Form 4 meets all procedural requirements, clearly disclosing withholding shares for tax on RSU vesting. Such actions are customary and do not suggest strategic timing or intent to signal. Continued service-based vesting over four years strengthens retention incentives for the CFO. There are no indications of insider concern or upcoming negative developments. Overall governance impact is neutral.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 7,123 | $17.31 | $123K |
Footnotes (1)
- Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 35,392 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.
